Goldman Sachs
ENZN

Goldman Sachs’s ENZON PHARMACEUTICALS INC ENZN Stock Holding History

Goldman Sachs’s Portfolio ENZN Stock Details ENZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-28,947
Closed -$14K – 7482
2016
Q1 		$14K Sell
28,947
-75,789
-72% -$37K ﹤0.01% 6841
2015
Q4 		$71K Buy
104,736
+6,900
+7% +$5.47K ﹤0.01% 6367
2015
Q3 		$95K Sell
97,836
-55,386
-36% -$68.2K ﹤0.01% 6520
2015
Q2 		$184K Sell
153,222
-4,034
-3% -$5.14K ﹤0.01% 6205
2015
Q1 		$167K Sell
157,256
-59,838
-28% -$61.9K ﹤0.01% 6140
2014
Q4 		$237K Sell
217,094
-155,274
-42% -$163K ﹤0.01% 6019
2014
Q3 		$403K Sell
372,368
-61,152
-14% -$75.5K ﹤0.01% 5471
2014
Q2 		$450K Sell
433,520
-11,666
-3% -$11.1K ﹤0.01% 5420
2014
Q1 		$459K Sell
445,186
-54,063
-11% -$55.8K ﹤0.01% 5365
2013
Q4 		$579K Buy
499,249
+173,716
+53% +$268K ﹤0.01% 5185
2013
Q3 		$547K Buy
325,533
+15,297
+5% +$28.3K ﹤0.01% 5104
2013
Q2 		$620K Buy
+310,236
New +$908K ﹤0.01% 4766

Other funds holding ENZN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
MCM
Monarch Capital Management Fort Wayne, Indiana $436M AUM 26.61% 1-Year Est. Return
CFA
CT Financial Advisors Chadds Ford, Pennsylvania $162M AUM 9.58% 1-Year Est. Return

Goldman Sachs's ENZN Position: Q2 2016 in Review

Goldman Sachs sold out of ENZON PHARMACEUTICALS INC (ENZN) in Q2 2016, closing a stake of 28,947 shares — an estimated $14K sold.

Goldman Sachs first reported a position in ENZN in Q2 2013 and held it in 12 quarters. The position peaked at $620K in Q2 2013. 10 funds tracked by Wall St. Rank hold ENZN as of Q2 2016.

  • Goldman Sachs reported no remaining ENZON PHARMACEUTICALS INC position as of Q2 2016 after selling out during the quarter.
  • Goldman Sachs sold 28,947 ENZON PHARMACEUTICALS INC shares in Q2 2016, an estimated $14K.
  • Goldman Sachs first reported a position in ENZON PHARMACEUTICALS INC in Q2 2013 and held it in 12 quarters.
  • Goldman Sachs's ENZON PHARMACEUTICALS INC position peaked at $620K in Q2 2013.
  • 10 funds tracked by Wall St. Rank held ENZON PHARMACEUTICALS INC as of Q2 2016.

Based on Goldman Sachs's 13F filing for Q2 2016, filed 15 Aug 2016.